Privia Health Group (NASDAQ:PRVA) CEO Parth Mehrotra Sells 41,999 Shares

Privia Health Group, Inc. (NASDAQ:PRVA) CEO Parth Mehrotra sold 41,999 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $22.86, for a total value of $960,097.14. Following the completion of the sale, the chief executive officer owned 343,795 shares of the company’s stock, valued at approximately $7,859,153.70. This represents a 10.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Parth Mehrotra also recently made the following trade(s):

• On Friday, March 6th, Parth Mehrotra sold 21,440 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total value of $496,336.00.

Privia Health Group Trading Down 3.6%

PRVA stock traded down $0.83 during trading on Tuesday, reaching $22.47. 1,025,433 shares of the stock were exchanged, compared to its average volume of 813,068. The firm’s 50 day moving average is $23.03 and its 200 day moving average is $23.60. The firm has a market cap of $2.78 billion, a P/E ratio of 132.18, a price-to-earnings-growth ratio of 1.49 and a beta of 0.82. Privia Health Group, Inc. has a twelve month low of $18.77 and a twelve month high of $26.51.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The firm had revenue of $541.17 million during the quarter, compared to the consensus estimate of $516.61 million. During the same quarter in the previous year, the company posted $0.21 earnings per share. The company’s quarterly revenue was up 17.4% on a year-over-year basis. As a group, analysts predict that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Institutional Trading of Privia Health Group

A number of institutional investors and hedge funds have recently modified their holdings of PRVA. Bayban bought a new position in Privia Health Group during the fourth quarter valued at about $26,000. Invesco Ltd. raised its position in Privia Health Group by 5.1% in the fourth quarter. Invesco Ltd. now owns 427,615 shares of the company’s stock worth $10,139,000 after acquiring an additional 20,652 shares during the period. Wellington Management Group LLP boosted its stake in Privia Health Group by 3.8% in the fourth quarter. Wellington Management Group LLP now owns 233,446 shares of the company’s stock valued at $5,535,000 after acquiring an additional 8,531 shares during the last quarter. Millennium Management LLC grew its position in shares of Privia Health Group by 19.0% during the 4th quarter. Millennium Management LLC now owns 702,744 shares of the company’s stock valued at $16,662,000 after acquiring an additional 112,428 shares during the period. Finally, Gotham Asset Management LLC increased its stake in shares of Privia Health Group by 22.4% during the 4th quarter. Gotham Asset Management LLC now owns 36,995 shares of the company’s stock worth $877,000 after purchasing an additional 6,773 shares during the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PRVA has been the topic of a number of recent research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $36.00 price objective on shares of Privia Health Group in a research note on Thursday, February 26th. Stephens reissued an “overweight” rating and set a $32.00 target price on shares of Privia Health Group in a research report on Thursday, December 4th. Truist Financial upped their target price on shares of Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Wolfe Research set a $31.00 price target on shares of Privia Health Group in a research report on Tuesday, January 6th. Finally, Citigroup decreased their price objective on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.00.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.